1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Spasticity - Epidemiology Forecast to 2030

Spasticity - Epidemiology Forecast to 2030

  • February 2021
  • 77 pages
  • ID: 6028054
  • Format: PDF
  • Delve Insight


Table of Contents

‘Spasticity – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Spasticity, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Spasticity Disease Understanding
Spasticity is defined as a condition in which certain muscles are continuously contracted. This contraction results in stiffness or tightness of the muscles and can interfere with normal movement, speech, and gait. It is also known as a motor disease which is characterized by a velocity-dependent increase in tonic stretch reflexes with exaggerated tendon jerks, resulting from hyper-excitability of the stretch reflex, as one component of the upper motor neuron syndrome.
Spasticity is usually caused by damage to the portion of the brain or spinal cord that controls voluntary movement. The damage causes a change in the balance of signals between the nervous system and the muscles. This imbalance leads to increased activity in the muscles. Spasticity is generally found in conditions where the brain or spinal cord are damaged or fail to develop normally; these include cerebral palsy, multiple sclerosis, spinal cord injury, and acquired brain injury including stroke.

Spasticity Epidemiology
The Spasticity epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of our report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The total prevalent cases of Spasticity patients are increasing in 7MM during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Spasticity symptoms epidemiology segmented as the Prevalent Population of Spasticity, Gender-Specific Spasticity Prevalence, and Spasticity prevalence by causes. The report includes the prevalent scenario of Spasticity symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise - Spasticity Epidemiology
The epidemiology segment also provides the Spasticity epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent cases of Spasticity associated in 7MM countries were 4,481 in 2020.
• As per the estimates, the United States has the largest prevalent population of Spasticity.
• Among the EU5 countries, Germany had the highest prevalent cases of Spasticity, followed by Italy. On the other hand, Spain had the lowest incident cases, with 227 cases in 2020 in EU5.

Scope of the Report
• The Spasticity report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
• The Spasticity Epidemiology Report and Model provide an overview of the risk factors and global trends of Spasticity in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Spasticity in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Spasticity.
• The report provides the segmentation of the Spasticity epidemiology by gender-specific spasticity prevalence in 7MM.
• The report provides the segmentation of the Spasticity epidemiology by spasticity prevalence by different causes in 7MM.

Report Highlights

• 11-year Forecast of Spasticity epidemiology
• 7MM Coverage
• Prevalent Cases according to segmentation: Gender-Specific Spasticity Prevalence
• Prevalent Cases according to segmentation: Spasticity Prevalence by different causes

KOL Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM for the patient population of Spasticity?
• What are the key findings of the Spasticity epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Spasticity across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What are the disease risk, burdens, and unmet needs of the Spasticity?
• What are the currently available treatments of Spasticity?

Reasons to buy
The Spasticity epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Spasticity market
• Quantify patient populations in the global Spasticity market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Spasticity therapeutics in each of the markets covered
• Understand the magnitude of Transplant Incidence.
• Understand the magnitude of Spasticity Incidence.
• The Spasticity epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Spasticity Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
Multiple sclerosis (MS) is a potentially severe cause of neurological disability throughout adult life. Prevalence has increased substantially in many regions since 1990. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, published in Lancet Neurology 2019 was used as the source for current prevalence rates across various geographies. This was verified by country-specific recent data wherever available. According to a 2004 study by Rizzo et al. using North American Research Committee on MS (NARCOMS) Patient Registry data, it was found that up to 84% of MS patients suffer from some degree of spasticity with approximately a third of the patients suffering from moderate to severe disease. This study also highlighted the suboptimal treatment received by the patients with up to 22% of the diagnosed patients not receiving any treatment for their spasticity.
Stroke, which is a leading cause of adult disabilities in the United States. It is a highly prevalent condition presenting roughly 2% of the total adult population. (Ovbiagele and Nguyen-Huynh, 2011) A 2016 updated report by the American Heart Association concluded that approximately 795,000 people experience a stroke in America each year, with around 610,000 of those reported to be the first incidence of stroke. Post-stroke spasticity is a major health issue for stroke survivors.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Neurovascular Devices Market Research Report by Disease Pathology, by Devices, by End-User, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • October 2021
  • 192 pages

Neurovascular Devices Market Research Report by Disease Pathology (Aneurysm, Arteriovenous Malformation and Fistulas (AVM), and Ischemic Stroke), by Devices (Cerebral Angioplasty and Stenting Systems, ...

  • United States
  • Neurological Disorder
  • Pathology
  • Industry analysis


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on